Physician profile

Stuart L Blum

Cardiovascular Disease · Shreveport, LA

NPI 1073509535

$1,954.88

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $342.14 2019-2022
Sanofi-Aventis U.S. LLC $275.96 2019
Pfizer INC. $264.21 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $167.84 2019-2020
Amgen INC. $155.42 2019-2020
Janssen Pharmaceuticals, INC $146.33 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $143.67 2019-2020
Akcea Therapeutics, INC. $101.26 2019-2020
E.R. Squibb & Sons, L.L.C. $80.63 2019
Astellas Pharma US INC $41.45 2019-2020
Actelion Pharmaceuticals US, INC. $40.95 2019
Regeneron Healthcare Solutions, INC. $36.68 2019
Abiomed $34.22 2019-2021
Irhythm Technologies, INC. $32.59 2019-2020
Arbor Pharmaceuticals, INC. $29.07 2019
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Preventice Services, LLC $20.82 2019
Kowa Pharmaceuticals America, INC. $16.76 2019
Medtronic Vascular, INC. $13.18 2019
Amarin Pharma, INC. $11.70 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stuart L Blum

$1,954.88

in general payments reported 2019-2025

Years
2019-2022
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/229623/stuart-l-blum

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.